SIGA Announces $16M Procurement Orders For Its Monkeypox Treatment

  • SIGA Technologies Inc SIGA received approximately $16 million in international procurement orders for oral TPOXX (tecovirimat) in August and early September.
  • The orders include an approximate $10 million order by the European Commission and approximately $6 million of orders from two countries in the Asia Pacific region, one of which is a new customer.
  • The order from the European Commission is for emergency short-term stockpiling and/or deployment of oral TPOXX (tecovirimat) in connection with the monkeypox outbreak. 
  • Related: SIGA Tech Made The Smallpox Treatment As Post-9/11 Bioterrorism Defense.
  • In addition to procuring oral TPOXX through the funding of direct purchases, the European Commission is also coordinating country-level procurement through the use of a joint procurement mechanism. 
  • SIGA expects to complete the delivery of these most recent orders in 2022. To date this year, including the recent orders, SIGA has received approximately $76 million of international orders for oral TPOXX. It is expected that at least $65 million of these orders will be delivered in 2022.
  • Price Action: SIGA shares are up 0.39% at $10.32 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsMonkeypox
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!